2019 International Congress » Other

1:45pm-3:15pm

A case of hemimasticatory spasm with well therapeutic response to serial injections of botulinum toxin

SK. Yang, JJ. Lin (Changhua County, Taiwan)

1:45pm-3:15pm

A review of interactive voice response systems in Parkinson’s Disease

J. Domingues, T. Guerreiro, D. Branco, A. Rodrigues, R. Bouça-Machado, J. Ferreira (Aveiro, Portugal)

1:45pm-3:15pm

A Study of Microglial Metabolism in Neuroinflammation

T. Domenick, B. Cyr, R. Yost, M. Okun, V. Vedam-Mai (Gainesville, FL, USA)

1:45pm-3:15pm

Agreement Between the GAITRite® Walkway System and the Wearable Inertial Sensor BTS G-Walk® for Measurement of Gait Parameters

H. Horáková, K. Poláková, E. Růžička, H. Brožová (Prague, Czech Republic)

1:45pm-3:15pm

Automated Immunohistochemical Detection of Skin Depositions of Pathological alpha-Synuclein in Idiopathic REM Sleep Behavior Disorder and Parkinsonism

T-S. Tsao, A. Al-Qassabi, A. Racolta, KI. Taylor, W. Zago, RB. Postuma, S. Dziadek (Basel, Switzerland)

1:45pm-3:15pm

Botulinum toxin treatment of muscle spasms in a case of Satoyoshi syndrome

I. Bledsoe (San Francisco, CA, USA)

1:45pm-3:15pm

Can people with Parkinson’s disease rely on their coping capacity over time? A longitudinal study using the Sense of Coherence (SOC) scale

J. Andersson, G-M. Hariz, L. Forsgren (Umeå, Sweden)

1:45pm-3:15pm

Cerebral cavernous malformations and movement disorders

M. Polemikos, E. Hermann, J. Krauss (Hannover, Germany)

1:45pm-3:15pm

Cerebral palsy masqueraders in an adult movement disorder tertiary centre: when to investigate an alternative diagnosis?

S. Duarte, R. Martins, M. Magalhães (Porto, Portugal)

1:45pm-3:15pm

Certification of cause of death in patients with Parkinson’s Disease (PD)

M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm

Clinical Audit of Hospital Admissions for Parkinson Disease

HL. Lan, LW. Wei, ST. Shu Ting, KY. Kay Yaw, WL. Wing Lok, LT. Louis Cs (Singapore, Singapore)

1:45pm-3:15pm

Clinical Correlates of Genetic and Biomarker Profiles in Patients with Progressive Supranuclear Palsy: Data from the ARISE Study

H. Soares, Z. Jin, N. Fisseha, M. Gold, C. Locke, B. Rendenbach-Mueller, E. Smith, I. Suridjan, A. Vasanthakumar, N. Mendonca (Ludwigshafen, Germany)

1:45pm-3:15pm

Creutzfeld Jacob disease presenting with functional-appearing, bizarre movements without significant cognitive impairment

M. Mcgraw, Z. Grujic, P. Vittal, J. Pallone (Winfield, IL, USA)

1:45pm-3:15pm

CSF levels of NFL (neurofilament light chain) in Parkinsons’ disease patients

E. Papuć, K. Rejdak (Lublin, Poland)

1:45pm-3:15pm

Cultural bias in performance of motor tasks? Comparison between Japanese and German healthy adults

K. Otte, M. Suzuki, H. Röhling, R. Kuroiwa, S. Mansow-Model, M. Mori, H. Zimmermann, AU. Brandt, F. Paul, S. Hirano, S. Kuwabara, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm

Diagnostic journeys of people with Parkinson’s disease in Kenya, sub-Saharan Africa

N. Fothergill Misbah, K. Hampshire, S. Moffatt, J. Kwasa, J. Hooker, R. Walker (Newcastle Upon Tyne, United Kingdom)

1:45pm-3:15pm

Differential Gait Progression in idiopathic Parkinson’s disease with and without freezing of gait

A. Glover, L. Pillai, S. Doerhoff, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm

Digital biomarker sensor feature data reflect quality of life judgements (PDQ39) in recently diagnosed Parkinson’s disease patients

F. Lipsmeier, K. Taylor, E. Volkova-Volkmar, H. Staunton, R. Postuma, T. Kilchenmann, D. Wolf, Y. Zhang, WY. Cheng, A. Scotland, J. Schjodt-Eriksen, F. Boess, D. Ness, C. Gossens, A. Post, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm

Does information from the Personal KinetiGraph™ (PKG) influence neurologists´ treatment decisions?

M. Sundgren, P. Rousu, A. Johansson (Stockholm, Sweden)

1:45pm-3:15pm

Dopaminergic Neuroregeneration in the Diencephalon of 6-OHDA-Lesioned Adult Zebrafish-Based Parkinson’s Disease Model

Y. Vijayanathan, SM. Lim, MP. Tan, FT. Lim, AB. Abdul Majeed, K. Ramasamy (Kuala Lumpur, Malaysia)

1:45pm-3:15pm

Effect of Balanced Based Torso Weighting on gait in parkinsonism

D. Safarpour, M. Mancini, C. Murchison, S. Wood, A. Lesher, J. Duda, J. Morley (Philadelphia, PA, USA)

1:45pm-3:15pm

Effect of Medication Review on Reported Symptoms in Parkinson’s disease Patients

C. Stuijt, T. Laar (Groningen, Netherlands)

1:45pm-3:15pm

Factors Influencing Decision-Making About End of Life Care in Patients With Parkinson’s Disease and Their Family Members

R. Bužgová, R. Kozáková, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

1:45pm-3:15pm

Gender gap in scientific granting competitions in movement disorders – insights from a national Canadian funding agency

S. Appel-Cresswell, P. Blanchet, J. Wysocki, R. Postuma (Vancouver, BC, Canada)

1:45pm-3:15pm

Genetics of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) – A Preliminary Demographic profile

P. Kukkle, V. Goyal, R. Kandadai, R. Borgohain, H. Kumar, A. Mukherjee, A. Biswas, S. Das, U. Muthane, S. Desai, P. Wadia, P. Pal, R. Yadav, V. Ramprasad (Bangalore, India)

1:45pm-3:15pm

Gut Feelings about Parkinson’s Disease: The Influence of the Gut Microbiota in a Rodent Model

A. Gorecki, L. Preskey, M. Bakeberg, J. Kenna, C. Gildenhuys, S. Dunlop, F. Koengten, R. Anderton (Nedlands, Australia)

1:45pm-3:15pm

Healthcare Resource Utilization and Costs of Parkinson’s Disease Dementia With Psychosis in the US Medicare Population

J. Wetmore, H. Yan, M. Irfan, Y. Peng, D. Gilbertson, S. Li, N. Rashid, A. Shim (Minneapolis, MN, USA)

1:45pm-3:15pm

Hemi masticatory spasm (HMS) : Series of 7 cases

D. Radhakrishnan, V. Goyal, G. Shukla, M. Singh (New Delhi, India)

1:45pm-3:15pm

Hemifacial spasm management: 26-year experience

Y. Herrero-Infante, A. Rodriguez-Sanz, J. Mañez-Miró, F. Vivancos-Matellano (Madrid, Spain)

1:45pm-3:15pm

High Content Screening of synucleinopathy in primary cortical neurons : dissecting out the interplay between the basic synuclein pools

F. de Giorgi, E. Bezard, F. Ichas (Bordeaux, France)

1:45pm-3:15pm

Identifying In-Clinic Wearable Sensor Features that Predict Parkinson’s Disease Severity

A. Dowling, A. Mirelman, J. Hausdorff, M. Sela, O. Assais, N. Giladi, J. Cedarbaum (Cambridge, MA, USA)

1:45pm-3:15pm

Impact of subthalamic deep brain stimulation on sensorimotor and motor cortical oscillatory activity in free-moving hemiparkinsonian rats

A. Abdulbaki, T. Doll, J. Krauss, M. Alam, K. Schwabe (Hannover, Germany)

1:45pm-3:15pm

Inflammatory cytokines in Saudi Parkinson cohort

N. Alsomali, E. Al-Ofi, M. Obaid, A. Alrafiah (Riyadh, Saudi Arabia)

1:45pm-3:15pm

Inhibition of mitochondrial complexes induces unique transcriptomic and epigenetic profiles: implications to neurodegeneration induced movement disorders

R. Sathyanarayanan, S. Bharath (Bangalore, India)

1:45pm-3:15pm

Investigation into the causes of reduced caffeine levels in Parkinson’s disease

MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

1:45pm-3:15pm

Investigation of the protective efficacy of alpha-synuclein-specific antibodies in a novel neuronal cell model for synucleinopathies

A. Peukert, M. Höllerhage, W. Zago, G. Höglinger (Munich, Germany)

1:45pm-3:15pm

Language characteristics of picture description task by Hebrew speaking patients with Parkinson’s disease

D. Shpunt, S. Naor, N. Diamant, A. Faust-Socher, H. Shabtai, R. Peled, A. Migirov, T. Gurevich, Y. Manor (Tel Aviv, Israel)

1:45pm-3:15pm

Mechanisms underlying therapeutic group singing in persons with Parkinson’s disease

E. Stegemoller, A. Zaman, K. Diaz, E. Shirtcliff, M. Kohut (Ames, IA, USA)

1:45pm-3:15pm

Metabolomic Analysis of Fecal Matter from Parkinsonian Mice

V. Vedam-Mai, E. Gill, J. Koelmel, R. Yost, T. Garrett, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm

MicroRNA Expression in the Diagnosis of Parkinson’s Disease

J. Roy, D. Guévremont, A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

1:45pm-3:15pm

Modeling of Parkinson’s disease by damaging dopaminergic neurons

L. Toshpulatova, M. Kulmanova (Tashkent, Uzbekistan)

1:45pm-3:15pm

Movement disorders as a clinical feature of Subacute Sclerosing Pan Encephalitis: Expansion of phenotypic spectrum

D. Dash, M. Tripathi, R. Singh (Delhi, India)

1:45pm-3:15pm

Movement disorders associated with autoimmune encephalitis

A. Chouksey, S. Pandey (New Delhi, India)

1:45pm-3:15pm

Movement Disorders in Post Stroke Patients: A Retrospective Analysis

M. Christie, V. Laticevschi, R. Mehanna (Houston, TX, USA)

1:45pm-3:15pm

Neuropathological findings in a SPG4 gene mutation carrier

S. Forcén, I. Aldecoa, AM. Crespo, O. Ramos, L. Ispierto, R. álvarez, D. Vilas (Badalona, Spain)

1:45pm-3:15pm

Objective quantifiable assessment of nocturnal movements in patients with Parkinson’s disease using a wearable sensor

A. Mirelman, I. Hillel, L. Rochester, A. Nieuwboer, B. Bloem, L. Avanzino, S. Shema-Shiratzki, I. Maidan, T. Herman, J. Cederbaum, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm

Opsoclonus and ataxia in the setting of synchronous primary malignancies

H. Leal Bailey, S. Wijemanne Sarathkumara, R. Knightstep (San Antonio, TX, USA)

1:45pm-3:15pm

Parkinson’s disease in Middle East, North Africa and South Asia: Consensus from the MDS Task Force on the Middle East

H. Khalil, L. Chahine, J. Junaid Siddiqui, M. Salari, S. El-Jaafary, Z. Aldaajani, M. Abu Al-Melh, T. Mohammad, M. Abu Snineh, N. Syed, M. Bhatt, M. Habib, M. Habahbeh, S. Tabbal, B. Jeon, J. Bajwa (Irbid, Jordan)

1:45pm-3:15pm

Patient organisation collaboration to advance patient engagement in Parkinson’s research

N. Ratcliffe, K. Schroeder (New York, NY, USA)

1:45pm-3:15pm

Pilot testing of the Integrated Parkinson’s Disease Care Network: feasibility, efficacy outcomes and cost description analysis

T. Mestre, D. Kessler, J. Shen, A. Basndwah, H. Shinawi, C. Nussey, A. Ohman, S. Kumar, D. Côté, C. Liddy, K. Thavorn, M. Taljaard, D. Grimes (Ottawa, ON, Canada)

1:45pm-3:15pm

Plasma membrane Ca2+ Atpase 1 as a candidate to mediate the degeneration of dopaminergic neurons by inflammation in Parkinson’s disease

B. Erhardt, MS. Marcora, A. Delella Ezcurra, J. Casabona, R. Tarelli, L. Frenkel, P. Bochicchio, D. Bodin, B. Silva, V. Cavaliere Candedo, MI. Farías, C. Ferrari, M. Allo, C. Höcht, A. Chernomoretz, E. Castaño, MC. Leal, F. Pitossi (Capital Federal, Argentina)

1:45pm-3:15pm

Post-stroke movement disorders: an analysis of 24 cases

M. Burzhunova, N. Garabova, L. Geraskina (Moscow, Russian Federation)

1:45pm-3:15pm

Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in de-novo diagnosed Parkinson patients

F. Lipsmeier, K. Taylor, E. Volkova-Volkmar, R. Postuma, T. Kilchenmann, D. Wolf, Y. Zhang, W. Cheng, A. Scotland, J. Schjodt-Eriksen, F. Boess, D. Ness, C. Gossens, A. Post, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm

Prevalence of chronic kidney disease in patients with idiopathic Parkinson’s disease in a tertiary care hospital in Mexico City

S. Isais-Millan, CA. Rojas-Guerrero, A. Arriaga, M. Rodriguez-Violante, D. Zuñiga-Garcia, RO. Millan-Guerrero, V. Campos-Gasga, V. Garcia-Barrera, R. Santos-Montero (Colima, Mexico)

1:45pm-3:15pm

Restless Genital Syndrome in a patient with Dementia with Lewy Body

M. Abu Al-Melh, M. Farghal, B. Al-Failakawii (Kuwait, Kuwait)

1:45pm-3:15pm

Rhythmic disorders in idiopathic RBD: a potential new marker for future PD?

V. Cochen Decock, D. Verbizier, C. Geny, S. Dalla Bella (Montpellier, France)

1:45pm-3:15pm

STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease

D. Rodriguez-Martin, C. Pérez-López, A. Samà, M. Pié, A. Català, J. Cabestany, A. Rodríguez-Molinero (Vilanova I Geltrú, Spain)

1:45pm-3:15pm

Stiff Limb Syndrome Progressing to Stiff Man Syndrome in a non-diabetic man

T. Ali, D. Ginjupally, Z. Guduru (Lexington, KY, USA)

1:45pm-3:15pm

Study on the effect of levodopa administration on serum zinc levels in Parkinson’s disease patients

H. Matsuyama, K. Matsuura, H. Ishikawa, Y. Hirata, N. Kato, A. Niwa, Y. Narita, H. Tomimoto (Tsu, Japan)

1:45pm-3:15pm

SWALLOWING VIDEOENDOSCOPY IN PATIENTS WITH PARKINSON’S DISEASE WITH DEEP BRAIN STIMULATION

T. Alves, N. Oliveira, G. Diaféria, M. Palumbo, MG. Ghilardi, E. Fonoff, M. Padovani (São Paulo, Brazil)

1:45pm-3:15pm

Systematic Assessment of 10 diagnostic marker candidates in biological fluids for Parkinson’s disease

B. Mollenhauer, R. Gera, N. Kruse, R. Barbour, W. Zago, S. Schade, B. Otte, C. Trenkwalder (South San Francisco, CA, USA)

1:45pm-3:15pm

The cognitive profiles differ among freezing of gait subtypes in Parkinson’s disease

J. Longhurst, J. Caldwell, A. Ritter, V. Mishra, B. Bluett, M. Landers (Las Vegas, NV, USA)

1:45pm-3:15pm

The effect of levodopa on speech in advanced Parkinson’s Disease: acoustic analysis and correlation with motor features and dyskinesia

F. Cavallieri, C. Budriesi, A. Gessani, V. Fioravanti, E. Menozzi, S. Contardi, F. Valzania, F. Antonelli (Reggio Emilia, Italy)

1:45pm-3:15pm

Tongue Myokymia and Earache as a unique presentation Associated with Local Tongue Pathology: A Case Report and Review of Literature

N. Merghany, W. Ibrahim, S. Nasr (Cairo, Egypt)

1:45pm-3:15pm

Trends in first line therapy for PD in Wales: A 16 year observational study

K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane (Cardiff, United Kingdom)

1:45pm-3:15pm

Update from the international MDSGene initiative: International team science to perform genotype-phenotype correlations for hereditary movement disorders

S. Petkovic, S. Schaake, J. Huang, H. Madoev, A. Rasheed, K. Lohmann, C. Klein, C. Marras (Luebeck, Germany)

1:45pm-3:15pm

Use of syringe driver in End of Life Care in Parkinson’s Disease (PD)

N. Butt, M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm

Utility of a smartphone app in discretely assessing and monitoring symptoms of Parkinson’s disease

N. Shaafi Kabiri, A. Best, S. Johnson, B. Ho, G. Eden, B. Dupee, M. Fedorovsky, J. Severson, D. Amato, B. Severson, J. Bhangu, J. Cosman, M. Erb, K. Thomas (Boston, MA, USA)

1:45pm-3:15pm

Wearable sensor use and monitoring effect of dopamine replacement therapy on motor parameters in a real life clinical setting

A. Podlewska, D. van Wamelen, A. Sauerbier, V. Leta, D. Trivedi, M. Parry, K. Ray Chaudhuri (Lodnon, United Kingdom)

1:45pm-3:15pm

Wearable versus marker-free technologies: does it matter for clinical gait analysis?

K. Otte, D. Drebinger, H. Röhling, T. Vater, D. Kroneberg, M. Voigt, B. Kayser, S. Mansow-Model, AU. Brandt, F. Paul, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm

Wide distribution of alpha-synuclein oligomers in Creutzfeldt-Jakob disease detected by a novel proximity ligation assay

R. Valenti-Azcarate, I. Martinez-Valbuena, C. Caballero, I. Marcilla Garcia, G. Marti, M. Carmona-Abellan, M. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)